Xcell Biosciences key facts
as of Oct 2026- Developer of a bench-top primary cell control system designed to advance immunotherapy research and manufacturing, empowering scientists with better tools for cell maintenance, expansion, and control.
- Xcell Biosciences is valued at approximately $65.5M as of Oct 2026 (last reported valuation).
- It has raised $60.4M across 3 recorded rounds; the latest was Later Stage VC ($27.5M) in Dec 2024.
- Notable investors include Lightspeed Venture Partners, Viking Global Investors, DST Global, Berkeley SkyDeck, Alexandria Venture Investments — 21 tracked in total.
- Xcell Biosciences has filed 3 Form Ds with the SEC since 2017, most recently Dec 2024 ($1.4M sold to 5 investors).
- Status: Privately Held (backing).
Xcell Biosciences's last reported valuation, Sep 2021. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch Xcell Biosciences: the Monday email on marks, rounds and moves
Xcell Biosciences funding rounds
3 roundsWho backs Xcell Biosciences
21+Xcell Biosciences valuation
Xcell Biosciences's last reported valuation was $65.5 million in Sep 2021. No priced round, secondary trade or fund mark has surfaced since.
How much has Xcell Biosciences raised?
Xcell Biosciences has raised $60.4 million across 3 recorded rounds since 2017. The largest was a $27.5 million later-stage round in Dec 2024.
Xcell Biosciences has filed 3 Form Ds with the SEC since 2017, most recently in Dec 2024 ($1.4 million sold to 5 investors).
Xcell Biosciences investors
21 investors are on record for Xcell Biosciences, including Lightspeed Venture Partners, Viking Global Investors, DST Global and Berkeley SkyDeck. By type, the record holds 5 venture capital firms and 1 hedge fund. The later-stage round in Dec 2024 drew 12 investors.
Comparable companies
Comparable discovery tools (healthcare) names by valuation on PrivateMarketView: Nature's Toolbox ($71 million), Vitrivax ($69.4 million) and Algen ($24 million).
About Xcell Biosciences
Developer of a bench-top primary cell control system designed to advance immunotherapy research and manufacturing, empowering scientists with better tools for cell maintenance, expansion, and control. The company's technology supports a range of primary cell types, including immune, stem, and tumor cells, enabling clients with predictive therapy development and improved clinical outcomes.
- Industry
- Discovery Tools (Healthcare)
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2012
- Employees
- 29
- Website
- xcellbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.